{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:23:28Z","timestamp":1792499008195,"version":"4.5.0"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T00:00:00Z","timestamp":1691712000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    H syndrome is a rare autosomal recessive genetic disorder characterized by the following clinical features: cutaneous hyperpigmentation, hypertrichosis, hepatosplenomegaly, heart anomalies, hearing loss, hypogonadism, short stature, hallux valgus, hyperglycemia, fixed flexion contractures of the toe joints, and the proximal interphalangeal joints. In rare cases, autoinflammatory and lymphoproliferative manifestations have also been reported. This disorder is due to loss-of-function mutations in\n                    <jats:italic>SLC29A3<\/jats:italic>\n                    gene, which encode the equilibrative nucleoside transporter ENT3. This deficiency leads to abnormal function and proliferation of histiocytes. H syndrome is part of the R-group of histiocytosis. We report two different cases, one was diagnosed in adulthood and the other in childhood. The first case reported is a 37-year-old woman suffering from H syndrome with an autoinflammatory systemic disease that begins in adulthood (fever and diffuse organ\u2019s infiltration) and with cutaneous, articular, auditory, and endocrinological manifestations since childhood. The second case reported is a 2-year-old girl with autoinflammatory, endocrine, and cutaneous symptoms (fever, lymphadenopathy, organomegaly, growth delay, and cutaneous hyperpigmentation). Homozygous mutations in\n                    <jats:italic>SLC29A3<\/jats:italic>\n                    confirmed the diagnosis of H syndrome in both cases. Each patient was treated with Tocilizumab with a significant improvement for lymphoproliferative, autoinflammatory, and cutaneous manifestations. Both cases were reported to show the multiple characteristics of this rare syndrome, which can be diagnosed either in childhood or in adulthood. In addition, an overview of the literature suggested Tocilizumab efficiency.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2023.1061182","type":"journal-article","created":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T13:23:36Z","timestamp":1691760216000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":24,"title":["H syndrome treated with Tocilizumab: two case reports and literature review"],"prefix":"10.3389","volume":"14","author":[{"given":"Robin","family":"Jacquot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurine","family":"Jouret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu Gerfaud","family":"Valentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u00ebl","family":"Richard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvan","family":"Jamilloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Rousset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Emile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Haroche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Steinm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Zekre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Belot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Seve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2008.09.013","article-title":"The H syndrome is caused by mutations in the nucleoside transporter hENT3","volume":"83","author":"Molho-Pessach","year":"2008","journal-title":"Am J Hum Genet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.90672.2008","article-title":"Facilitated mitochondrial import of antiviral and anticancer nucleoside drugs by human equilibrative nucleoside transporter-3","volume":"296","author":"Govindarajan","year":"2009","journal-title":"Am J Physiology-Gastrointestinal Liver Physiol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaad.2008.03.021","article-title":"The H syndrome: A genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations","volume":"59","author":"Molho-Pessach","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.02.015","article-title":"Macrophages in tissue repair, regeneration, and fibrosis","volume":"44","author":"Wynn","year":"2016","journal-title":"Immunity"},{"key":"B5","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1136\/jclinpath-2020-206733","article-title":"Rosai-Dorfman disease: an overview","volume":"73","author":"Bruce-Brand","year":"2020","journal-title":"J Clin Pathol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-690636","article-title":"Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages","volume":"127","author":"Emile","year":"2016","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.09.019","article-title":"H syndrome: The first 79 patients","volume":"70","author":"Molho-Pessach","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3109\/01676830.2013.814689","article-title":"Orbital rosai-dorfman disease: A literature review","volume":"32","author":"McClellan SF","year":"2013","journal-title":"Orbit"},{"key":"B9","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12969-017-0204-y","article-title":"H syndrome: 5 new cases from the United States with novel features and responses to therapy","volume":"15","author":"Bloom","year":"2017","journal-title":"Pediatr Rheumatol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1159\/000338886","article-title":"Identification of two novel mutations in SLC29A3 encoding an equilibrative nucleoside transporter (hENT3) in two distinct Syrian families with H syndrome: expression studies of SLC29A3 (hENT3) in human skin","volume":"224","author":"Farooq","year":"2012","journal-title":"Dermatology"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000931","article-title":"Overview of castleman disease","volume":"135","author":"Dispenzieri","year":"2020","journal-title":"Blood"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2010-3639","article-title":"Mevalonate kinase deficiency: A survey of 50 patients","volume":"128","author":"Bader-Meunier","year":"2011","journal-title":"Pediatrics"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/DAD.0b013e3181b28572","article-title":"H syndrome: recently defined genodermatosis with distinct histologic features. A morphological, histochemical, immunohistochemical, and ultrastructural study of 10 cases","volume":"32","author":"Doviner","year":"2010","journal-title":"Am J Dermatopathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jdermsci.2009.09.011","article-title":"The H syndrome: Two novel mutations affecting the same amino acid residue of hENT3","volume":"57","author":"Molho-Pessach","year":"2010","journal-title":"J Dermatol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2012-2255","article-title":"Mutation in the SLC29A3 gene: A new cause of a monogenic, autoinflammatory condition","volume":"131","author":"Melki","year":"2013","journal-title":"PEDIATRICS"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15082","article-title":"H syndrome: A review of treatment options and a hypothesis of phenotypic variability","volume":"34","author":"Nofal","year":"2021","journal-title":"Dermatol Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/s12887-016-0595-9","article-title":"Unusual presentation of Rosai-Dorfman disease in a 14-month-old Italian child: a case report and review of the literature","volume":"16","author":"di Dio","year":"2016","journal-title":"BMC Pediatr"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2016-3148","article-title":"Tocilizumab for the treatment of SLC29A3 mutation positive PHID syndrome","volume":"140","author":"Rafiq","year":"2017","journal-title":"Pediatrics"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s10875-016-0301-6","article-title":"A case of SLC29A3 spectrum disorder\u2014unresponsive to multiple immunomodulatory therapies","volume":"36","author":"Mistry","year":"2016","journal-title":"J Clin Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annder.2019.09.389","article-title":"Efficacit\u00e9 du tocilizumab dans le syndrome H, un cas clinique","volume":"146","author":"Hamann","year":"2019","journal-title":"Ann Dermatol Venereol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12969-021-00586-2","article-title":"Patient with H syndrome, cardiogenic shock, multiorgan infiltration, and digital ischemia","volume":"19","author":"Ventura-Espejo","year":"2021","journal-title":"Pediatr Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"e249191","DOI":"10.1136\/bcr-2022-24919","article-title":"Improvement of SLC29A3 spectrum disorder-related sensorineural hearing loss after initiation of IL-6 inhibitor","volume":"15","author":"Gunderman","year":"2022","journal-title":"BMJ Case Rep"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s42000-022-00352-3","article-title":"Atypical comorbidities in a child considered to have type 1 diabetes led to the diagnosis of SLC29A3 spectrum disorder","volume":"21","author":"Besci","year":"2022","journal-title":"Hormones"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14375","article-title":"Mycophenolate mofetil treatment of an H syndrome patient with a SLC29A3 mutation","volume":"33","author":"Behrangi","year":"2020","journal-title":"Dermatol Ther"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/pr.2013.187","article-title":"Advances in the pathogenesis and treatment of systemic juvenile idiopathic arthritis","volume":"75","author":"Correll","year":"2014","journal-title":"Pediatr Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1016\/S0140-6736(08)60454-7","article-title":"Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial","volume":"371","author":"Yokota","year":"2008","journal-title":"Lancet"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1061182\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T13:23:44Z","timestamp":1691760224000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1061182\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,11]]},"references-count":26,"alternative-id":["10.3389\/fimmu.2023.1061182"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1061182","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,11]]},"article-number":"1061182"}}